Sofosbuvir-Velpatasvir

Phase 3

Sofosbuvir-Velpatasvir is one of 2 therapeutic programs targeting HEPATITIS C VIRUS CHRONIC INFECTION. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

HEPATITIS C VIRUS CHRONIC INFECTIONActive, not recruiting

HEPATITIS C VIRUS CHRONIC INFECTIONPhase 3

Active, not recruiting

Competition

Competitive Landscape

1 competitor in HEPATITIS C VIRUS CHRONIC INFECTION

#DrugCompanyPhaseTrials

Sofosbuvir-Velpatasvir

AAtea Pharmaceuticals, Inc.

Phase 3

1 2

Bemnifosbuvir-Ruzasvir

AAtea Pharmaceuticals, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

HEPATITIS C VIRUS CHRONIC INFECTION

NCT07037277

Clinical

Trials by Indication[1]

HEPATITIS C VIRUS CHRONIC INFECTION1 trial

An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in a Phase 3 Randomized, Controlled, Open-label Study

Active, not recruiting·AAtea Pharmaceuticals, Inc.·Phase 3·NCT07037277·880 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sofosbuvir-Velpatasvir. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Sofosbuvir-Velpatasvir. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Atea Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: AAtea Pharmaceuticals, Inc.

Sofosbuvir-Velpatasvir

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

HEPATITIS C VIRUS CHRONIC INFECTION1 trial

References

Drug Info

Quick Facts

Related News